Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

Background: Although lenvatinib has become the standard therapy for hepatocellular carcinoma (HCC), the high incidence rate of adverse events (AEs) is an issue. This study aimed to clarify the AEs of lenvatinib and the therapeutic impact of five days-on/two days-off administration (i.e., weekends-of...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancers (Basel)
मुख्य लेखकों: Iwamoto, Hideki, Suzuki, Hiroyuki, Shimose, Shigeo, Niizeki, Takashi, Nakano, Masahito, Shirono, Tomotake, Okamura, Shusuke, Noda, Yu, Kamachi, Naoki, Nakamura, Toru, Masuda, Atsutaka, Sakaue, Takahiko, Tanaka, Toshimitsu, Nakano, Dan, Sakai, Miwa, Yamaguchi, Taizo, Kuromatsu, Ryoko, Koga, Hironori, Torimura, Takuji
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: MDPI 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226076/
https://ncbi.nlm.nih.gov/pubmed/32325921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041010
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन